| Outcome Measures: |
Primary: Vascular stiffness, Vascular stiffness will be measured by pulse wave velocity and augmentation index and compared between anlodipine and aliskiren., 8 weeks|Endothelial function, Access endothelial function by peripheral arterial tonometry and brachial flow-mediated vasodilation and compare it between anlodipine and aliskiren., 8 weeks|Renin activity and concentration, Access plasma renin activity and concentration and compare it between anlodipine and aliskiren., 8 weeks | Secondary: Compare drug effects in office blood pressure measurements to those obtained by home blood pressure monitoring and ambulatory blood pressure monitoring, Compare drug effects in office blood pressure measurements to those obtained by home blood pressure monitoring and ambulatory blood pressure monitoring, 8 weeks|Assess drugs effects in renin-angiotensin-aldosterone system (RAAS) and correlate it to renin concentration/mass and plasmatic renin activity, Assess drugs effects in RAAS and correlate it to renin concentration/mass and plasmatic renin activity, 8 weeks|Correlation of drug effects and uric acid plasmatic concentration, Correlation of drug effects and uric acid plasmatic concentration, 8 weeks|Correlation of drug effects and glomerular filtration rate, Correlation of drug effects and glomerular filtration rate, 8 weeks|Correlation of drug effects and microalbuminuria, Correlation of drug effects and microalbuminuria, 8 weeks|Correlation of drug effects and left ventricular mass and function (systolic and diastolic), Correlation of drug effects and left ventricular mass and function (systolic and diastolic), 8 weeks
|
